Fig. 5: Therapeutic efficacy of neutralizing human monoclonal antibodies against SARS-CoV-2 infection.
From: Potently neutralizing and protective human antibodies against SARS-CoV-2
a, Mice were inoculated intranasally with MA-SARS-CoV-2 and 12 hours later given the indicated monoclonal antibody treatments by intraperitoneal injection. Viral burden in the lungs at 2 dpi was measured by plaque assay. The number of mice per group (n) is indicated. Data represent one experiment. b, Mice were treated with anti-IFNAR1 and transduced with AdV-hACE2. Mice were then inoculated intranasally with wild-type SARS-CoV-2 and 12 hours later given the indicated monoclonal antibody treatments by intraperitoneal injection. Viral burden in the lungs at 2 dpi was measured by plaque assay. Two experiments were performed with n =3 to 5 mice per group. Controls for plaque neutralization assay performance were included: lung homogenates from individual mice (n = 3) that were treated with isotype control monoclonal antibody were mixed 1:1 (v:v) with lung homogenates from individual naive untreated mice or antibody-cocktail-treated mice. The latter mixture ensures that neutralization of infection did not occur ex vivo after tissue homogenization. For a, b, measurements from individual mice and median titre are shown, and each group was compared to the isotype-control-treated group using a Kruskal–Wallis ANOVA with Dunn’s post hoc test. c, Expression of cytokine and chemokine genes was measured by qPCR analysis in lungs from b. Measurements from individual mice and median values are shown. Groups were compared using the two-sided Mann–Whitney U-test. The number of mice per group (n) is indicated. Two experiments were performed with n = 3 to 5 mice per group.
